A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Abstract Text:

Keith L Kirkwood,Fei Li,Jill E Rogers,Jodie Otremba,Derek D Coatney,Jaclynn M Kreider,Nisha J D'Silva,Sarvajit Chakravarty,Sundeep Dugar,Linda S Higgins,Andrew A Protter,Satyanarayana Medicherla,

In the oral microbial environment, Gram-negative bacterial derived lipopolysaccharide (LPS) can initiate inflammatory bone loss as seen in periodontal diseases. p38 Mitogen-activated protein kinase (MAPK) signaling is critical to inflammatory cytokine and LPS-induced cytokine expression, which may contribute toward periodontal bone loss. The purpose of this proof-of-principle study was to evaluate the ability of an orally active p38alpha MAPK inhibitor (SD-282) to reduce periopathogenic LPS-induced alveolar bone loss in an experimental rat model. Five groups of Sprague-Dawley rats received one of the following treatments: LPS injected to the palatal gingiva adjacent to the maxillary molars three times per week for 8 weeks, LPS plus two doses of SD-282 (15 or 45 mg/kg) twice daily by oral gavage, or control groups given drug vehicle (1% polyethylene glycol) or SD-282 (45 mg/kg) only. Baseline and 8-week alveolar bone loss was assessed by microcomputed tomography (microCT) and histological examination. LPS induced severe bone loss over this time period, whereas control groups were unchanged from baseline measurements. Both doses of SD-282 showed significant protection from LPS-induced bone loss. Bone area and volumetric analysis of maxillas by microCT indicated significant loss of bone volume with LPS treatment, which was blocked with the p38 inhibitor. Histological examination indicated significantly fewer tartate-resistant acid phosphatase-positive osteoclasts and a significant decrease in interleukin (IL)-6, IL-1beta, and tumor necrosis factor alpha expression in p38 inhibitor-treated groups compared with LPS groups by immunostaining. Results from this in vivo study suggest that orally active p38 MAPK inhibitors can reduce LPS-induced inflammatory cytokine production and osteoclast formation and protect against LPS-stimulated alveolar bone loss.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Publishing Authors By Initials

KL Kirkwood,F Li,JE Rogers,J Otremba,DD Coatney,JM Kreider,NJ D'Silva,S Chakravarty,S Dugar,LS Higgins,AA Protter,S Medicherla,

For similar enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-serine-threonine kinases: mitogen-activated protein kinases: p38 mitogen-activated protein kinases research abstracts see: enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-serine-threonine kinases: mitogen-activated protein kinases: p38 mitogen-activated protein kinases research

PUBMED ID PMID:

MEDLINE DATE:

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of pharmacology and experimental thera

VOLUME: 320

Page Numbers: 56-63

Journal Abbreviation: J. Pharmacol. Exp. Ther.

ISSN: 0022-3565

DAY: 13

MONTH: 10

YEAR: 2006

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376362

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Keywords Mesh Terms:

KEYWORDS: p38 Mitogen-Activated Protein Kinases

MESH TERMS: physiology

Chemical & Substance for Abstract: A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. Information

Substance Name: p38 Mitogen-Activated Protein Kinases

Registry Number: EC 2.7.1.37

Grant and Affiliation Information for A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

AFFILIATION: Department of Periodontics and Oral Medicine, University of Michigan, 1011 N. University Ave., Ann Arbor, MI 48109-1078, USA. klkirk@umich.edu

Country: United States

AGENCY: United States NIAMS

GRANT: P30AR46024

ACRONYM: AR

MEDLINETA: J Pharmacol Exp Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss Related Publications

• A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.